Billing for independent infusion centers, specialty practice infusion suites, hospital outpatient infusion departments and home infusion providers, done inside the EHR you already run.
On an infusion claim the drug is the most expensive line, and it is lost on small details: billing units that do not match the HCPCS descriptor, a JZ modifier left off a single-dose vial, an 11-digit NDC missing from a Medicaid claim, or a chart with no stop time. Missing or invalid prior authorization caused 17% of denials in the Luxen claim audit of 61,400 claims. Luxen checks drug, time and approval before every infusion claim goes out.
On this page
Infusion billing services code, submit and appeal claims for drug infusions and injections in offices, infusion centers, hospital outpatient departments and homes. Each claim pairs a drug HCPCS code in exact units with CPT administration codes set by documented time. In the Luxen claim audit, JW or JZ drug waste modifiers were missing on 11% of single-dose vial claims.
Each infusion setting bills under different rules.
Service lines we bill alongside the infusion: buy-and-bill drug lines, same-day E/M visits with modifier 25, injections, hydration, authorizations and patient billing after coinsurance.
Infusion revenue leaks through drug units, administration times and approvals. Our denial and AR recovery team works these claims oldest dollars first. Amounts: 2026 Medicare national non-facility rates.
| Scenario | Codes | What goes wrong | $ at stake per claim | Luxen audit finding |
|---|---|---|---|---|
| Biologic billed as a therapeutic infusion | 96365 instead of 96413 | Medicare uses chemotherapy administration codes for monoclonal antibodies | $66.13 on the first hour | Coding and modifier errors caused 21% of denials |
| Infusion runs past 1 hour 30 minutes | 96413 with 96415 | No stop time, so the additional hour is never billed | $28.39 per hour | Start and stop times checked on every visit |
| Single-dose vial with no waste modifier | J code with JW or JZ | Claim returned as unprocessable | Full drug line | JW or JZ drug waste modifiers were missing on 11% of single-dose vial claims |
| Hospital outpatient infusion without site of care approval | Drug HCPCS plus 96413 | Payer approved an office or home site | Full drug and administration | Missing or invalid prior authorization caused 17% of denials |
| Medicaid drug line without an NDC | J code with N4 NDC | 11-digit NDC or unit qualifier missing | Full drug line | NDC and units matched before submission |
| Hydration during the drug infusion | 96360, 96361 | Concurrent hydration is not separately reportable | $33.40, recouped on audit | Hydration time checked against the drug times |
Codes follow drug type, route, order and documented minutes. Our certified medical coding team codes from the administration record.
| Code | What it covers | 2026 national non-facility |
|---|---|---|
| 96360 | Hydration, initial, 31 minutes to 1 hour | $33.40 |
| 96361 | Hydration, each additional hour | $13.03 |
| 96365 | Therapeutic or diagnostic IV infusion, initial hour | $67.14 |
| 96366 | Therapeutic infusion, each additional hour | $21.38 |
| 96367 | Sequential infusion of a new drug, first hour | $29.73 |
| 96368 | Concurrent infusion | $20.71 |
| 96372 | Subcutaneous or intramuscular injection | $15.36 |
| 96374 | IV push, single or initial drug | $37.74 |
| 96375 | IV push, each additional sequential new drug | $15.70 |
| 96413 | Chemotherapy or complex biologic infusion, initial hour | $133.27 |
| 96415 | Chemotherapy infusion, each additional hour | $28.39 |
| 96417 | Sequential chemotherapy infusion, first hour | $66.47 |
Total non-facility RVUs times the $33.4009 conversion factor, before locality adjustment.
In the office, Medicare allows one initial code per encounter, chosen by the primary reason for the visit, unless protocol requires two separate IV sites. Hospital outpatient departments follow a hierarchy: chemotherapy services, then therapeutic infusions, pushes and injections, then hydration.
Bill 96374 once for the first IV push and 96375 for each sequential push of a different drug. When an infusion is the initial service, the first push becomes 96375. A repeat push of the same drug is 96376, reported by facilities only.
Medicare Part B pays most separately payable drugs at 106% of average sales price (ASP). Sequestration takes 2% off the final payment after coinsurance. Qualifying biosimilars get ASP plus 8% of the reference product ASP for five years, starting October 1, 2022 for those already paid then. Commercial drug rates follow the contract, and underpayments against contracted rates appeared on 7.8% of paid claims in the Luxen claim audit.
Units come from the HCPCS descriptor, not the vial: J1745 is infliximab, excludes biosimilar, 10 mg, so a 500 mg dose is 50 units. Under 42 CFR 447.520, Medicaid collects NDCs on physician-administered drugs, typically the 11-digit NDC with the N4 qualifier in loop 2410 and a unit qualifier of F2, GR, ML or UN. For J3490, J3590 or J9999, Medicare wants quantity 1 with the drug name and dosage in item 19.
JW reports the amount discarded from a single-dose container; JZ reports that nothing was discarded and has been required since July 1, 2023. Neither applies to multiple-dose vials. JW or JZ drug waste modifiers were missing on 11% of single-dose vial claims in the Luxen claim audit.
Since January 1, 2025, 340B covered entities report TB, not JG, on separately payable Part B drugs. The CY 2026 OPPS 340B remedy offset stays at 0.5% of non-drug payments.
Since January 1, 2021, qualified home infusion therapy suppliers enrolled in Part B bill professional services on the 837P to the A/B MAC; enrollment is part of our credentialing service. Payment is per infusion drug administration calendar day, a day a skilled professional is in the home while the drug is given.
| Category | Drugs | First visit, 2026 | Later visits, 2026 |
|---|---|---|---|
| 1: G0088, G0068 | IV anti-infective, pain management, chelation, pulmonary hypertension, inotropic | $231.36 | $190.22 |
| 2: G0089, G0069 | Subcutaneous immunotherapy or other subcutaneous infusion | $312.60 | $257.04 |
| 3: G0090, G0070 | IV chemotherapy or other highly complex drug | $388.89 | $319.76 |
2026 national amounts, before geographic adjustment.
Under LCD L33794, when an external infusion pump is covered, the drug that requires it and the supplies are covered too, billed to the DME MAC.
In-home IVIG coverage became permanent on January 1, 2024. Q2052 pays $442.19 per infusion date in 2026 for services and supplies, one unit per date, billed to the DME MAC separately from the drug.
Contracts built on the NHIA National Coding Standard pay a per diem S code for pharmacy services, supplies and equipment, with the drug and nursing billed separately.
Medicare applies chemotherapy administration codes to monoclonal antibodies and other biologic response modifiers, naming infliximab and rituximab (Medicare Claims Processing Manual, Chapter 12, section 30.5). Billing 96365 instead loses $66.13 on the first hour. Coding and modifier errors caused 21% of denials in the Luxen claim audit.
Medicare does not pay 99211, with or without modifier 25, billed with a drug infusion or chemotherapy administration code (Chapter 12, section 30.5). Each one is $24.38 denied or recouped. The top three denial reasons accounted for 58% of denied dollars in the average practice (Luxen billing reviews).
JZ is required when nothing is discarded from a single-dose container, and claims without JW or JZ may be returned as unprocessable (CMS JW and JZ modifier FAQs). 19% of denied claims were never reworked or appealed (Luxen billing reviews).
Hydration concurrent with other drug administration is not separately reportable (NCCI Policy Manual, Chapter XI). Each unsupported 96360 risks $33.40. 63% could not name their top three denial reasons (Luxen Practice Manager Survey 2026).
UnitedHealthcare hospital outpatient approvals last no more than 6 months (UnitedHealthcare site of care policy). Infusing elsewhere denies drug and administration. Missing or invalid prior authorization caused 17% of denials in the Luxen claim audit.
We run the revenue cycle from eligibility to zero balance inside the practice management system you already use. How full-service billing works.
Certified coders review charges against your documentation and payer rules before the claim goes out, so the denial is prevented rather than appealed. Medical coding.
Aged and denied claims are worked to resolution, then the upstream cause is fixed so the same claims stop coming back. Denials and AR recovery.
Benefits are verified and authorizations secured before the appointment, which is the cheapest place in the cycle to stop a denial. Eligibility and prior authorization.
Statements, balance questions and payment plans are handled by the same team that worked the claim. Patient billing.
Payer enrollment and re-credentialing are tracked through to approval, so a lapsed credential never quietly stops payment. Credentialing.
A HIPAA-trained front-office assistant working inside your EHR on calls, scheduling, intake and referrals, alongside the billing team. Medical virtual assistant.
We work inside the systems your infusion program already runs.
We sign the BAA before access and bill from the administration records, drug logs and authorizations your team already keeps.
2 weeks
from a signed BAA to our team working your claims
About 3 weeks
to the first recovered payments on aged AR
20+ years
combined billing and coding experience
Luxen claim audit (61,400 claims audited, Jan 2025 to Jun 2026) and Luxen client data (38 client practices, Jan 2024 to Jun 2026):
Drug units, NDC information, and discarded amounts were not consistently aligned with the administration record. Luxen added a pre-bill review, reduced infusion-drug denials from 16.5% to 4.2%, and recovered $118,400.
Practice Administrator, independent infusion center
We were scheduling treatments before confirming that the approved drug, date range, and site matched the order. Luxen connected authorization tracking to the infusion schedule and reduced held claims from $232,000 to $39,000.
Revenue Cycle Director, multi-specialty infusion practice
Full engagements are written up in our dental practice case study and our ambulance billing case study.
UnitedHealthcare's Provider Administered Drugs Site of Care policy (effective September 1, 2026) covers hospital outpatient infusion only when a criterion is met, such as medical instability, vascular access problems or severe prior reactions, and hospital approvals last no more than 6 months. Cigna's Medication Administration Site of Care policy gives a one-time 30-day approval to transition a patient.
From January 1, 2026, Minnesota Statutes 62M.07 bars prior authorization of antineoplastic cancer treatment consistent with NCCN guidelines, except medications, so the infused drug still needs approval. See our Minnesota medical billing guide. Delaware carriers must decide drug requests within 2 business days of a clean pre-authorization, or the service is deemed preauthorized. See Delaware medical billing rules.
Approved drug, units, date range and site against the order and schedule; reauthorization dates ahead of the next dose; and which plan pays the drug. Eligibility and coverage errors caused 24% of denials in the Luxen claim audit, so eligibility and prior authorization work runs before the first dose.
3% to 6% of collections
Luxen's pricing generally falls between 3% and 6% of collections, depending on claim volume, specialty, payer mix, and how much of the revenue cycle your practice hands over.
Higher-volume practices usually land toward the lower end. Smaller or more complex practices land higher because there is more work per account. There is no setup fee and no exit fee, and the agreement runs month to month with 30 days notice.
A lower fee attached to weak billing is still expensive. The number that matters is what your collections do after you hire someone.
Luxen charges 3% to 6% of collections, depending on drug volume, payer mix and authorization workload. No setup or exit fee.
| Service line | Monthly collections | Luxen at 3% | Luxen at 6% |
|---|---|---|---|
| Infusion and injectable drugs | $110,000 | $3,300 | $6,600 |
| Drug administration and visits | $30,000 | $900 | $1,800 |
| Home infusion services | $10,000 | $300 | $600 |
| Total | $150,000 | $4,500 | $9,000 |
| Cost | In-house | Luxen |
|---|---|---|
| Monthly | $11,850 (7.9% of collections) | $4,500 to $9,000 |
| Annual | $142,200 | $54,000 to $108,000 |
| When a biller leaves | Open biller roles took a median 67 days to fill | No gap in coverage |
| Terms | Salaries, benefits and software | Month to month, 30 days notice |
Fully loaded in-house billing cost 7.9% of collections for practices under $2M, across 96 practices that shared payroll data (Luxen billing reviews).
| Partner type | Drug unit and NDC checks | Site of care tracking | Reporting | Terms |
|---|---|---|---|---|
| In-house biller | Depends on one person | Shared with front desk | Built by your staff | Payroll and turnover |
| Generalist billing company | Usually after denial | Often not included | Standard aging | Often annual |
| Specialty infusion billing company | Drug-focused | Sometimes a separate fee | Varies | Varies |
| EHR vendor RCM | Vendor templates | Limited | Inside the platform | Bundled with software |
| Luxen | Pre-bill check on every drug line | Included | Monthly denials and AR by drug and payer | Month to month, 30 days notice |
Compare medical billing companies, or see what full-service medical billing covers.
A 30-minute look at your AR ageing, denial reasons and payer mix. You leave knowing what is recoverable, what we would work first and what it would cost.
We sign a business associate agreement before anyone touches your system. Your named team then works inside the practice management system and clearinghouse you already use. Nothing is migrated, and claims are being worked within two weeks of the signed BAA.
Aged and denied claims come first because that is revenue you have already earned. Most practices see the first recovered payments inside three weeks.
Once the backlog is moving, we take over the agreed part of the daily cycle: eligibility, coding review, submission, posting, denials and patient balances.
You know who owns your claims. The team works inside the practice management system and EHR you already run, with no migration.
Claims are coded by certified coders against your documentation and payer rules. Automation handles the repetitive checks so people spend their time on the claims that need judgment.
We sign a business associate agreement before accessing protected health information, and access is limited to the named people on your account.
We look at your AR ageing, volume, payer mix and denial profile first, then tell you what we believe is recoverable and what it would cost.
A billing company is a poor fit if you are not willing to share visibility into your billing, if the vendor uses a rotating pool of people who never learn your practice, or if it cannot explain why your claims are being denied. Be wary of anyone promising large collection increases before they have seen your AR ageing. The right partner makes your revenue cycle more visible, not less.
Each visit is billed in two parts: the drug, coded with its HCPCS code in units matching the descriptor, and the administration, coded with CPT 96360 to 96417 from documented start and stop times. Medicare pays most Part B drugs at 106% of ASP, and Medicaid requires the 11-digit NDC. Medicare single-dose vial claims also need JW or JZ.
Luxen charges 3% to 6% of collections, depending on drug volume, payer mix and authorization workload. For a practice collecting $150,000 a month, that is $4,500 to $9,000. Fully loaded in-house billing cost 7.9% of collections for practices under $2M in Luxen billing reviews.
About 2 weeks from signed BAA to working claims; median time from signed BAA to first claims worked was 9 business days across Luxen clients. We start with open authorizations and the oldest recoverable claims, so first recovered payments arrive in about 3 weeks. There is no migration, setup fee or exit fee.
Yes. We work inside the EHR, practice management and pharmacy systems you already use, including Epic, OncoEMR, athenaOne, eClinicalWorks, ModMed and WellSky CareTend. We sign a BAA before access.
Not while it runs at the same time as the drug: concurrent hydration is not separately reportable under the NCCI Policy Manual. Hydration given before or after the drug for a separate medical reason can be reported as 96361 when it runs more than 30 minutes and the drug infusion is the initial service.
Thirty minutes, no deck and no fee. We look at what is sitting past 90 days and where your denials cluster, and you leave knowing what is recoverable, what we would work first, and what it would cost.
Book a Billing Review%20(1).avif)
